FR2727117B1 - - Google Patents

Info

Publication number
FR2727117B1
FR2727117B1 FR9413861A FR9413861A FR2727117B1 FR 2727117 B1 FR2727117 B1 FR 2727117B1 FR 9413861 A FR9413861 A FR 9413861A FR 9413861 A FR9413861 A FR 9413861A FR 2727117 B1 FR2727117 B1 FR 2727117B1
Authority
FR
France
Prior art keywords
pct
diseases
sec
date
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9413861A
Other languages
English (en)
French (fr)
Other versions
FR2727117A1 (fr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9413861A priority Critical patent/FR2727117A1/fr
Application filed filed Critical
Priority to US08/836,199 priority patent/US6114388A/en
Priority to JP51662296A priority patent/JP4128618B2/ja
Priority to PT95940329T priority patent/PT792167E/pt
Priority to ES95940329T priority patent/ES2161915T3/es
Priority to DK95940329T priority patent/DK0792167T3/da
Priority to EP95940329A priority patent/EP0792167B1/fr
Priority to CA002205557A priority patent/CA2205557C/en
Priority to NZ297040A priority patent/NZ297040A/xx
Priority to PCT/FR1995/001517 priority patent/WO1996015810A1/fr
Priority to AU41811/96A priority patent/AU694825B2/en
Priority to DE69521521T priority patent/DE69521521T2/de
Priority to AT95940329T priority patent/ATE202487T1/de
Publication of FR2727117A1 publication Critical patent/FR2727117A1/fr
Application granted granted Critical
Publication of FR2727117B1 publication Critical patent/FR2727117B1/fr
Priority to GR20010401567T priority patent/GR3036710T3/el
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polyamides (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR9413861A 1994-11-18 1994-11-18 Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun Granted FR2727117A1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
FR9413861A FR2727117A1 (fr) 1994-11-18 1994-11-18 Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
AU41811/96A AU694825B2 (en) 1994-11-18 1995-11-17 Monofunctional and/or polyfunctional polylysine conjugates
PT95940329T PT792167E (pt) 1994-11-18 1995-11-17 Conjugados monofuncionais e/ou polifuncionais da polilisina
ES95940329T ES2161915T3 (es) 1994-11-18 1995-11-17 Conjugados monofuncionales y/o polifuncionales de la polilisina.
DK95940329T DK0792167T3 (da) 1994-11-18 1995-11-17 Monofunktionelle og/eller polyfunktionelle polylysin-konjugater
EP95940329A EP0792167B1 (fr) 1994-11-18 1995-11-17 Conjugues monofonctionnels et/ou polyfonctionnels de la polylysine
US08/836,199 US6114388A (en) 1994-11-18 1995-11-17 Monofunctional and/or polyfunctional polylysine conjuages
NZ297040A NZ297040A (en) 1994-11-18 1995-11-17 Mono- or polyfunctional polylysine conjugates
PCT/FR1995/001517 WO1996015810A1 (fr) 1994-11-18 1995-11-17 Conjugues monofonctionnels et/ou polyfonctionnels de la polylysine
JP51662296A JP4128618B2 (ja) 1994-11-18 1995-11-17 単官能性および／または多官能性ポリリシン結合体
DE69521521T DE69521521T2 (de) 1994-11-18 1995-11-17 Mono- oder polyfunktionelle konjugate von polylysine
AT95940329T ATE202487T1 (de) 1994-11-18 1995-11-17 Mono- oder polyfunktionelle konjugate von polylysine
CA002205557A CA2205557C (en) 1994-11-18 1995-11-17 Monofunctional and/or polyfunctional polylysine conjugates
GR20010401567T GR3036710T3 (en) 1994-11-18 2001-09-26 Monofunctional and/or polyfunctional polylysine conjugates

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9413861A FR2727117A1 (fr) 1994-11-18 1994-11-18 Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun

Publications (2)

Publication Number Publication Date
FR2727117A1 FR2727117A1 (fr) 1996-05-24
FR2727117B1 true FR2727117B1 (enExample) 1997-02-21

Family

ID=9468953

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9413861A Granted FR2727117A1 (fr) 1994-11-18 1994-11-18 Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun

Country Status (14)

Country Link
US (1) US6114388A (enExample)
EP (1) EP0792167B1 (enExample)
JP (1) JP4128618B2 (enExample)
AT (1) ATE202487T1 (enExample)
AU (1) AU694825B2 (enExample)
CA (1) CA2205557C (enExample)
DE (1) DE69521521T2 (enExample)
DK (1) DK0792167T3 (enExample)
ES (1) ES2161915T3 (enExample)
FR (1) FR2727117A1 (enExample)
GR (1) GR3036710T3 (enExample)
NZ (1) NZ297040A (enExample)
PT (1) PT792167E (enExample)
WO (1) WO1996015810A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO104396A0 (en) * 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Antiviral linear polymers
DE69835201T2 (de) 1997-04-18 2007-06-14 Novartis Ag Neoglycoproteine
FR2763853B1 (fr) * 1997-05-28 2000-01-07 Oreal Association d'un retinoide avec un polymere polyamine
DE19732139C2 (de) * 1997-07-25 2002-10-10 Max Planck Gesellschaft Mesomorphe Komplexe aus Vitamin A-Säure und kationischen Polyelektrolyten, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
FR2773808B1 (fr) * 1998-01-20 2000-05-05 Sagebo Composes susceptibles de pieger les ions metalliques, leur procede d'obtention et leur utilisation
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6686446B2 (en) * 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
GB9811059D0 (en) * 1998-05-23 1998-07-22 Univ Strathclyde Polyamino acid vesicles
DE69923322T2 (de) * 1998-07-30 2005-12-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung
CA2372526A1 (en) * 1999-05-10 2000-11-16 Michael D. Wyrsta Methods and compositions for controlled polypeptide synthesis
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
CA2759572A1 (en) * 2002-08-08 2004-02-19 Baylor College Of Medicine Isolation and identification of t cells
WO2004020673A1 (en) * 2002-08-28 2004-03-11 Millipore Corporation Compositions of solution for sequencing reaction clean-up
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
ATE499104T1 (de) * 2005-03-24 2011-03-15 Univ Emory Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
FR2886153B1 (fr) * 2005-05-27 2009-04-10 Gemac Sa Composition destinee au traitement de la sclerose en plaques
CA2651328A1 (en) * 2006-05-05 2007-11-15 Opexa Therapeutics T-cell vaccine
FR2905868B1 (fr) * 2006-09-18 2012-12-21 Gemac Composition destinee au traitement de la sclerose laterale amyotrophique
EP2107913B1 (en) 2006-12-22 2012-02-15 Croma-Pharma Gesellschaft m.b.H. Use of thiolated polysaccharides for tissue augmentation
FR2913335B1 (fr) 2007-03-06 2009-06-05 Michel Geffard Utilisation de conjugues d'acides gras et de poly-l-lysine pour lutter contre des microorganismes pathogenes.
EP2085082A1 (en) * 2008-01-29 2009-08-05 Nutromnia S.R.L. Treatment of cognitive decline
SG193926A1 (en) * 2011-04-12 2013-11-29 Nestec Sa Nutritional compositions including branched chain fatty acids and methods of using same
PL3116887T3 (pl) 2014-03-13 2021-09-06 Universität Basel Ligandy węglowodanowe, które wiążą się z przeciwciałami igm przeciwko glikoproteinie związanej z mieliną
FR3030524B1 (fr) * 2014-12-17 2017-01-20 Hydro-Fill Utilisation de pll pour ameliorer la stabilite de molecules en solution
CN108026134A (zh) 2015-09-16 2018-05-11 巴塞尔大学 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体
FR3048616B1 (fr) * 2016-03-14 2018-04-06 Polyneuros Polycomplexes de composes poly-lysine pour la prevention et/ou la lutte contre la sclerose laterale amyotrophique
FR3122571B1 (fr) * 2021-05-10 2023-05-12 Hydro Fill Tech Compositions et leur utilisation pour rétablir la perméabilité intestinale et/ou prévenir ou lutter contre des maladies multifactorielles
FR3122573B1 (fr) * 2021-05-10 2024-03-29 Hydro Fill Tech Compositions de conjugués poly-lysine et de micelles et/ou de copolymères de poly-lysine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1979000515A1 (en) * 1978-01-16 1979-08-09 Univ Boston Method of effecting cellular uptake of molecules
DE3546150A1 (de) * 1985-06-24 1987-01-22 Hoechst Ag Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung
GB9004538D0 (en) * 1990-02-28 1990-04-25 Offord Robin E Chemical compounds
AU1674292A (en) * 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
AU4534593A (en) * 1992-06-12 1994-01-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
FR2705234B1 (fr) * 1993-05-19 1995-08-04 Geffard Michel Utilisation de molécules reconnues par des autoanticorps de sérums humains pour le diagnostic ou le traitement du SIDA.

Also Published As

Publication number Publication date
JPH10511643A (ja) 1998-11-10
PT792167E (pt) 2001-12-28
US6114388A (en) 2000-09-05
NZ297040A (en) 1999-05-28
CA2205557C (en) 2008-07-15
DK0792167T3 (da) 2001-10-29
CA2205557A1 (en) 1996-05-30
AU4181196A (en) 1996-06-17
WO1996015810A1 (fr) 1996-05-30
EP0792167A1 (fr) 1997-09-03
GR3036710T3 (en) 2001-12-31
AU694825B2 (en) 1998-07-30
ES2161915T3 (es) 2001-12-16
FR2727117A1 (fr) 1996-05-24
JP4128618B2 (ja) 2008-07-30
ATE202487T1 (de) 2001-07-15
EP0792167B1 (fr) 2001-06-27
DE69521521T2 (de) 2002-04-25
DE69521521D1 (de) 2001-08-02

Similar Documents

Publication Publication Date Title
AU694825B2 (en) Monofunctional and/or polyfunctional polylysine conjugates
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
PL328858A1 (en) Immunogenous peptides
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
AU4165797A (en) Methods and compositions for the treatment of bone resorption disorders, including osteoporosis
MD1745B2 (en) 4,5-dimethyl-N-2-propenyl-2-(trimethylsilyl)-3-thiophencarboxamide, fungicidal composition on base thereof and method of plants diseases control
AU4347796A (en) Use of nebivolol as an anti-atherogenic
BG104943A (en) Biodegradable sustained-release alginate gels
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
AU2291097A (en) Novel phenanthridines substituted in the 6 position
AP9801269A0 (en) Prostaglandin agonists.
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
HU9403343D0 (en) New pharmaceutical uses of krill enzymes
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
GB9712966D0 (en) Novel chalcones
EP0830456A4 (en) INSULATED FrpB NUCLEIC ACID MOLECULE AND CORRESPONDING VACCINE
EA199700151A1 (ru) Композиция для чрескожного введения
SI1082131T1 (en) Immunoregulator
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
CA2184635A1 (fr) Marqueurs genetiques utilises conjointement pour le diagnostic de la maladie d'alzheimer, methode et kit de diagnostic
GB9509321D0 (en) Methods of and substances for inhibiting oxidative enzymes
BG105275A (en) Tan-1057 derivatives
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease

Legal Events

Date Code Title Description
ST Notification of lapse
CA Change of address
CJ Change in legal form
TP Transmission of property